3-(9-fluorenylmethyloxycarbonyl)amino-2-methylbenzoic acid | 1072901-47-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 3-(9-fluorenylmethyloxycarbonyl)amino-2-methylbenzoic acid
• 英文别名: Fmoc-3-amino-2-methylbenzoic acid；3-(9H-fluoren-9-ylmethoxycarbonylamino)-2-methylbenzoic acid
• CAS: 1072901-47-3
• 化学式: C₂₃H₁₉NO₄
• 分子量: 373.408
• InChiKey: PZBXPHGPGVUOMO-UHFFFAOYSA-N

物化性质

• 沸点：
  548.3±45.0 °C(Predicted)
• 密度：
  1.323±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  Fmoc-L-亮氨酸 、 3-(9-fluorenylmethyloxycarbonyl)amino-2-methylbenzoic acid 、 N-alpha-芴甲氧羰基-N-epsilon-叔丁氧羰基-L-赖氨酸 、 Fmoc-D-丙氨酸 在 N,N-二异丙基乙胺 、 哌啶 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以0.119 g的产率得到(3-((R)-2-((S)-2-((R)-2-((S)-2-((R)-2-((S)-2-amino-6-((tert-butoxycarbonyl)amino)hexanamido)propanamido)-4-methylpentanamido)propanamido)-6-((tert-butoxycarbonyl)amino)hexanamido)propanamido)-2-methylbenzoyl)-D-alanine
  参考文献：
  名称：

  Processable Cyclic Peptide Nanotubes with Tunable Interiors

  摘要：

  A facile route to generate cyclic peptide nanotubes with tunable interiors is presented. By incorporating 3-amino-2-methylbenzoic acid in the D,L-alternating primary sequence of a cyclic peptide, a functional group can be presented in the interior of the nanotubes without compromising the formation of high aspect ratio nanotubes. The new design of such a cyclic peptide also enables one to modulate the nanotube growth process to be compatible with the polymer processing window without compromising the formation of high aspect ratio nanotubes, thus opening a viable approach toward molecularly defined porous membranes.

  DOI：

  10.1021/ja2063082
• 作为产物：
  描述：

  2-甲基-3-氨基苯甲酸 、 9-芴甲基-N-琥珀酰亚胺基碳酸酯 在 碳酸氢钠 作用下， 以 1,4-二氧六环 、 水 为溶剂， 以80%的产率得到3-(9-fluorenylmethyloxycarbonyl)amino-2-methylbenzoic acid
  参考文献：
  名称：

  Processable Cyclic Peptide Nanotubes with Tunable Interiors

  摘要：

  A facile route to generate cyclic peptide nanotubes with tunable interiors is presented. By incorporating 3-amino-2-methylbenzoic acid in the D,L-alternating primary sequence of a cyclic peptide, a functional group can be presented in the interior of the nanotubes without compromising the formation of high aspect ratio nanotubes. The new design of such a cyclic peptide also enables one to modulate the nanotube growth process to be compatible with the polymer processing window without compromising the formation of high aspect ratio nanotubes, thus opening a viable approach toward molecularly defined porous membranes.

  DOI：

  10.1021/ja2063082

文献信息

• LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY
  申请人：Bittermann Holger

  公开号：US20130131321A1

  公开（公告）日：2013-05-23

  The present invention relates to the use for affinity purification of an antibody or an fragment of an antibody, of a ligand-substituted matrix comprising a support material and at least one ligand covalently bonded to the support material, the ligand being represented by formula (I) wherein Sp is a spacer group; v is 0 or 1; Am is an amide group —NR 1 —C(O)—, and wherein either NR 1 is attached to Ar 1 and —C(O)— is attached to Ar 2 , or —C(O)— is attached to Ar 1 and NR 1 is attached to Ar 2 ; and R 1 is hydrogen or C 1 to C 4 alkyl, preferably hydrogen or methyl; and more preferably hydrogen; Ar 1 is a divalent 5- or 6-membered substituted or unsubstituted aromatic ring; Ar 2 is 5- or 6-membered heterocyclic aromatic ring which is (a) attached to a further 5- or 6-membered aromatic ring via a single bond; or (b) fused to a further 5- or 6-membered aromatic ring as part of a multicyclic ring system; or (c) attached to at least one substituent selected from C 1 to C 4 alkyl; C 2 to C 4 alkenyl; C 2 to C 4 alkynyl; a halogen; C 1 to C 4 haloalkyl; hydroxyl-substituted C 1 to C 4 alkyl; C 1 to C 4 alkoxy; hydroxyl-substituted C 1 to C 4 alkoxy; C 1 to C 4 alkylamino; C 1 to C 4 alkylthio; and combinations thereof.

  本发明涉及使用具有支持材料和至少一种共价键合到支持材料的配体的替代基矩阵，用于亲和纯化抗体或抗体片段，其中该配体由式(I)表示，其中Sp是一个空间基团；v为0或1；Am是一个酰胺基团-NR1-C（O）-，其中NR1连接到Ar1，-C（O）-连接到Ar2，或-C（O）-连接到Ar1，NR1连接到Ar2；R1是氢或C1到C4烷基，优选氢或甲基，更优选氢；Ar1是二价的5-或6-成员取代或未取代芳香环；Ar2是5-或6-成员的杂环芳香环，它(a)通过单键连接到另一个5-或6-成员的芳香环；或（b）作为多环环系统的一部分与另一个5-或6-成员的芳香环融合；或（c）连接到至少一个取代基，所述取代基选择自C1到C4烷基；C2到C4烯基；C2到C4炔基；卤素；C1到C4卤代烷基；羟基取代的C1到C4烷基；C1到C4烷氧基；羟基取代的C1到C4烷氧基；C1到C4烷基氨基；C1到C4烷基硫基；以及其组合。
• Human testis expressed patched like protein
  申请人：Aeomica, Inc.

  公开号：EP1229046A2

  公开（公告）日：2002-08-07

  The invention provides isolated nucleic acids that encode HTPL, including two isoforms, and fragments thereof, vectors for propagating and expressing HTPL nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel HTPL isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human HTPL nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human HTPL gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the HTPL nucleic acids, proteins, and antibodies of the present invention.

  本发明提供了编码 HTPL（包括两种异构体）的分离核酸及其片段、繁殖和表达 HTPL 核酸的载体、包含本发明核酸和载体的宿主细胞、新型 HTPL 异构体的蛋白质、蛋白质片段和蛋白质融合体及其抗体。本发明进一步提供了包含人类 HTPL 核酸的转基因细胞和非人类生物体，以及靶向干扰人类 HTPL 基因内源直向同源物的转基因细胞和非人类生物体。本发明进一步提供了本发明核酸、蛋白质和抗体的药物制剂，以及基于本发明 HTPL 核酸、蛋白质和抗体的诊断、研究和治疗方法。
• A human protein kinase domain-containing protein
  申请人：Aeomica, Inc.

  公开号：EP1227156A2

  公开（公告）日：2002-07-31

  The invention provides isolated nucleic acids that encode a human protein kinase domain-containing portein (STTK), and fragments thereof, vectors for propagating and expressing STTK nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel STTK isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising STTK nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the STTK gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the STTK nucleic acids, proteins, and antibodies of the present invention.

  本发明提供了编码含人蛋白激酶结构域的门冬氨酸（STTK）的分离核酸及其片段、用于繁殖和表达STTK核酸的载体、包含本发明核酸和载体的宿主细胞、新型STTK异构体的蛋白质、蛋白质片段和蛋白质融合体及其抗体。本发明进一步提供了包含 STTK 核酸的转基因细胞和非人类生物体，以及定向破坏 STTK 基因内源直向同源物的转基因细胞和非人类生物体。本发明进一步提供了本发明核酸、蛋白质和抗体的药物制剂，以及基于本发明 STTK 核酸、蛋白质和抗体的诊断、研究和治疗方法。
• Human ralgds-like protein 3
  申请人：Aeomica, Inc.

  公开号：EP1229132A2

  公开（公告）日：2002-08-07

  The invention provides isolated nucleic acids that encode RGL3, and fragments thereof, vectors for propagating and expressing RGL3 nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel RGL3 isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human RGL3 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human RGL3 gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the RGL3 nucleic acids, proteins, and antibodies of the present invention.

  本发明提供了编码RGL3的分离核酸及其片段、用于繁殖和表达RGL3核酸的载体、包含本发明核酸和载体的宿主细胞、新型RGL3异构体的蛋白质、蛋白质片段和蛋白质融合体及其抗体。本发明进一步提供了包含人类 RGL3 核酸的转基因细胞和非人类生物体，以及靶向破坏人类 RGL3 基因内源直向同源物的转基因细胞和非人类生物体。本发明进一步提供了本发明核酸、蛋白质和抗体的药物制剂，以及基于本发明RGL3核酸、蛋白质和抗体的诊断、研究和治疗方法。
• Human gtp-rho binding protein 2
  申请人：Aeomica, Inc.

  公开号：EP1231216A2

  公开（公告）日：2002-08-14

  The invention provides isolated nucleic acids that encode human GRBP2, and fragments thereof, vectors for propagating and expressing human GRBP2 nucleic acids, host cells comprising the inucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the human GRBP2, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human GRBP2 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human GRBP2 gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the human GRBP2 nucleic acids, proteins, and antibodies of the present invention.

  本发明提供了编码人GRBP2的分离核酸及其片段、用于繁殖和表达人GRBP2核酸的载体、包含本发明核酸和载体的宿主细胞、人GRBP2的蛋白质、蛋白质片段和蛋白质融合体及其抗体。本发明进一步提供了包含人 GRBP2 核酸的转基因细胞和非人类生物体，以及靶向破坏人 GRBP2 基因内源直向同源物的转基因细胞和非人类生物体。本发明进一步提供了本发明的核酸、蛋白质和抗体的药物制剂，以及基于本发明的人GRBP2核酸、蛋白质和抗体的诊断、研究和治疗方法。